KOSDAQ - Delayed Quote KRW

Celltrion Pharm, Inc. (068760.KQ)

Compare
56,300.00
-600.00
(-1.05%)
At close: 3:30:25 PM GMT+9
Loading Chart for 068760.KQ
DELL
  • Previous Close 56,900.00
  • Open 56,900.00
  • Bid 56,000.00 x --
  • Ask 56,100.00 x --
  • Day's Range 55,600.00 - 58,500.00
  • 52 Week Range 47,238.09 - 114,095.23
  • Volume 138,494
  • Avg. Volume 216,552
  • Market Cap (intraday) 2.447T
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Mar 17, 2025 - Mar 21, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 27, 2006
  • 1y Target Est --

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea.

www.celltrionph.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 068760.KQ

View More

Performance Overview: 068760.KQ

Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

068760.KQ
0.71%
KOSPI Composite Index
3.75%

1-Year Return

068760.KQ
45.42%
KOSPI Composite Index
1.41%

3-Year Return

068760.KQ
39.37%
KOSPI Composite Index
15.95%

5-Year Return

068760.KQ
76.02%
KOSPI Composite Index
11.68%

Compare To: 068760.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 068760.KQ

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    2.47T

  • Enterprise Value

    2.60T

  • Trailing P/E

    133.77

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.18

  • Price/Book (mrq)

    6.34

  • Enterprise Value/Revenue

    5.95

  • Enterprise Value/EBITDA

    51.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.47%

  • Return on Assets (ttm)

    3.41%

  • Return on Equity (ttm)

    8.91%

  • Revenue (ttm)

    274.73B

  • Net Income Avi to Common (ttm)

    26.03B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    34.63B

  • Total Debt/Equity (mrq)

    63.34%

  • Levered Free Cash Flow (ttm)

    -20.1B

Research Analysis: 068760.KQ

View More

People Also Watch